Humans Female *Urinary Bladder Neoplasms/pathology *Carcinoma Transitional Cell/pathology Urinary Bladder/pathology Prognosis Proportional Hazards Models Meta-analysis Muscle-invasive bladder urothelial carcinoma Non-muscle-invasive bladder urothelial carcinoma Sex

Humans *Carcinoma Transitional Cell/pathology *Urinary Bladder Neoplasms/genetics DNA Methylation Neoplasm Recurrence Local/genetics Prognosis *Urologic Neoplasms/genetics/pathology Membrane Proteins/genetics Neoplasm Proteins/genetics Biomarkers Kaplan-Meier survival Meta-analysis Methylation Upper tract urothelial carcinoma

Humans Female Male Infant *Urinary Bladder Neoplasms/diagnosis/therapy/pathology *Carcinoma Transitional Cell/pathology Urinary Bladder/pathology Neoplasm Staging Cystoscopy Cystectomy/methods

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.

Administration Intravesical *Carcinoma Transitional Cell/pathology Humans Male Neoplasm Invasiveness/pathology Neoplasm Recurrence Local/pathology Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/therapy

*Carcinoma Transitional Cell/pathology Female Humans Male Neoplasm Invasiveness Nephroureterectomy Sweden *Urinary Bladder Neoplasms/pathology Swedish national guidelines Urothelial carcinoma non-muscle invasive bladder cancer upper tract urothelial carcinoma

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

*Carcinoma Transitional Cell/pathology/surgery Combined Modality Therapy Consensus Humans Neoplasm Invasiveness/pathology Quality of Life Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/drug therapy/surgery Bladder neoplasms Bladder preservation Expert consensus Multi-disciplinary treatment

*Carcinoma Transitional Cell/pathology Humans Prognosis Retrospective Studies *Ureteral Neoplasms *Urinary Bladder Neoplasms *Urologic Neoplasms/pathology Carcinoma Transitional Cell Pathology

Humans Biomarkers Tumor *Carcinoma in Situ/diagnosis *Carcinoma Transitional Cell/pathology Hyaluronan Receptors/metabolism Keratin-20/analysis/metabolism Ki-67 Antigen/metabolism Tumor Suppressor Protein p53/analysis/metabolism Urinary Bladder *Urinary Bladder Neoplasms/pathology Urothelium/chemistry/metabolism/pathology Bladder carcinoma Carcinoma in situ Carcinoma vesical Displasia Dysplasia Immunomarkes Inmunomarcadores

*Carcinoma Transitional Cell/pathology/radiotherapy Humans *Kidney Neoplasms Kidney Pelvis/pathology Prognosis *Ureteral Neoplasms/pathology *Urinary Bladder Neoplasms Adjuvant radiotherapy Prognostic Radiotherapy Survival Upper urinary tract urothelial carcinoma

Carcinoma Transitional Cell/pathology Disease-Free Survival Humans *Neoplasm Staging Prognosis Urinary Bladder/*pathology Urinary Bladder Neoplasms/*pathology Bladder urothelial carcinoma Meta-analysis Squamous differentiation

Carcinoma Transitional Cell/pathology/*radiotherapy/*surgery *Cystectomy Humans Neoplasm Invasiveness *Radiotherapy Adjuvant Urinary Bladder Neoplasms/pathology/*radiotherapy/*surgery Cystectomie Cystectomy Local recurrence Muscle-invasive bladder cancer Prognosis Pronostic Radiotherapy Radiothérapie Récidive locale Tumeur de vessie infiltrant le muscle

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Antineoplastic Agents/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Chemotherapy Adjuvant Cystectomy Cystoscopy Humans Lymph Node Excision Muscle Smooth/*pathology *Neoadjuvant Therapy Neoplasm Invasiveness *Organ Sparing Treatments Progression-Free Survival Proportional Hazards Models *Radiotherapy Adjuvant Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder preserving Cancer Muscle invasive Radical cystectomy Trimodal

Biomarkers Tumor/*urine Carcinoma Transitional Cell/pathology/*urine Gene Expression Regulation Neoplastic Humans Prognosis RNA Long Noncoding/*urine Urinary Bladder Neoplasms/pathology/*urine Bladder cancer biomarker diagnosis long non-coding RNA urothelial carcinoma–associated 1

Carcinoma Transitional Cell/pathology/*surgery Cystectomy/*methods Humans Kaplan-Meier Estimate Neoplasm Recurrence Local Risk Factors Urethra/*pathology Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/pathology/*surgery Bladder cancer Neobladder Radical cystectomy Urethral recurrence Urothelial carcinoma

Carcinoma Transitional Cell/pathology/*surgery Electrocoagulation/*methods Humans Length of Stay Muscle Smooth/pathology Neoplasm Invasiveness *Neoplasm Recurrence Local Operative Time Prospective Studies Retrospective Studies Urinary Bladder/pathology/*surgery Urinary Bladder Neoplasms/pathology/*surgery